APsense

  • Our Services

    We offer best-in-class research and consulting services pertaining to the markets of all geographies. Our experienced team of business analysts and consultants has mastered fundamental and advanced market research in diverse industries.

  • Syndicated Research

    Syndicated research is the most cost-effective market research approach, which gives an analytical outlook of the competitive positioning, product positioning, and size estimation of the market at the micro level. Our off-the-shelf reports offer key market insights that industry stakeholders require to base their business strategy on. Our syndicated research services empower our clients to meet diverse market objectives.

  • Customized Research

    we also deliver customized research services to address specific needs of our clients. With a vast pool of adroit analysts who are proficient in market research, we take pride in tailoring our research services to meet our clients’ definite requirements and aid their business growth.

  • Consulting Services

    Businesses, today, need to adapt themselves to the changes that transpire in the market. Staying abreast of the market trends, therefore, becomes imperative for accomplishing business objectives.

  • Our Vision

    To be the most trusted partner in our clients' success endeavors

Adenosine 5-Monophosphate Activated Protein Kinase (AMPK) Modulators Therapeutics - Pipeline Analysis 2018


Adenosine 5-monophosphate activated protein kinase (AMPK) plays an important role in regulation of homeostasis. Dysregulation of AMPK can result in many diseases which includes obesity and type 2 diabetes. Several studies have also suggested that AMPK are also associated with the development of neurological diseases and cancer.
Esperion Therapeutics Inc. is in the process of developing Bempedoic acid as a small molecule which acts as an AMPK stimulant for the treatment of hypercholesterolemia, dyslipidaemia, and hypertension. Betagenon AB, Boehringer Ingelheim International GmbH, and Poxel SA are some other companies having pipeline AMPK modulators for the management of several diseases.

Request to Get the Sample Pages at:  


The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials.
Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology and others.

Share:

Aurora Kinase Inhibitor Therapeutics - Pipeline Analysis 2019


Aurora kinase are proteins that function as mitotic regulators and are aberrantly expressed in cancerous cells. Aurora kinase inhibitors target these aberrantly expressed regulators, provides genetic stability and prevents tumorigenesis.
Several studies have demonstrated overexpression and amplification of aurora kinase in various haematological and solid cancers. Aurora kinase inhibitors when combined with other anti-cancer agents gives more positive results in variety of cancers. Better evaluation of aurora kinase inhibitors is required which raises the need of biomarkers, effective and novel therapeutic agents. Also, aurora kinase inhibitors selectivity targets cancer cells rather than healthy tissues, providing potential opportunities for more effective drug development with reduced adverse effects.
Request to Get the Sample Pages at: 
AstraZeneca PLC is in the process of developing AZD-2811 as a small molecule which acts as an aurora B inhibitor for the treatment of solid tumors. Some of the other companies having pipeline of aurora kinase inhibitors include AbbVie Inc., Merck & Co., Inc., and CASI Pharmaceuticals Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Share:

Hepatocyte Growth Factor (HGF) Inhibitor Therapeutics - Pipeline Analysis 2019

Hepatocyte growth factor (HGF) is secreted by human pancreatic stellate cells and present predominantly on cancer cells. Thus, HGF inhibitors has emerged as an effective therapy in preventing local tumor growth. Also, studies have demonstrated that HGF inhibitors are significantly more effective than Gemcitabine in inhibiting tumor angiogenesis and metastasis.


Image result for Hepatocyte Growth Factor

Studies have demonstrated that the HGF inhibitor can be a novel therapeutics that can be developed as a monotherapy or as combination therapy with RAS-RAF-MEK, AKT-mTOR, and EGFR inhibitors for the treatment of various human cancers. HGF inhibitors have shown potent antineoplastic effects in several clinical trials for the treatment of head and neck squamous cell carcinoma as HGF/c-Met pathway is directly involved in the development of a proliferative, invasive, and metastatic cancer.
Request to Get the Sample Pages at:   
AVEO Pharmaceuticals Inc. is in the process of developing Ficlatuzumab as a potent HGF inhibitor antibody that binds to the HGF ligand with high affinity and specificity to inhibit HGF/c-Met biological activities for the treatment of squamous cell carcinoma of the head and neck and acute myeloid leukemia. Galaxy Biotech LLC, Daiichi Sankyo Company Limited, and Taiho Pharmaceutical Co. are some other companies having HGF inhibitor pipeline.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Share:

Interleukin 8 Inhibitors Therapeutics - Pipeline Analysis 2019





Interleukin 8 is a chemokine produced by various immune cells. They promote angiogenesis, proliferation and development of cancerous cells. The other diseases which are associated with interleukin 8 are depression, schizophrenia, bipolar disorder, migraine, Alzheimer’s disease, colitis, rheumatoid arthritis, multiple sclerosis, asthma, allergic rhinitis, psoriasis, eczema and others.
Image result for Interleukin 8 Inhibitors
Interleukin 8 inhibitors therapies have shown improvements as anti-CXCL8 signalling inhibitors for the treatment of various diseases, including cancer and inflammatory diseases. Studies demonstrated that interleukin 8 can be indirectly targeted by mitogen activated protein kinase (MAPK) inhibitors, phosphatidylinositol-3-kinase (PI3K)/AKT inhibitors, and NF-κB inhibitors while direct targeting can be done by CXCL8 neutralizing antibodies, and other drug therapies such as Reparixin. Potent effects of interleukin 8 inhibitors therapeutics as chemo-modulators and anti-angiogenics are expected to treat various tumors.
Request to Get the Sample Pages at: 
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Share:

Mitogen-Activated Protein Kinase (MAPK) Inhibitors Therapeutics - Pipeline Analysis 2019


Mitogen-activated protein kinase (MAPK) are ubiquitous regulators of many cellular functions including cell proliferation, cellular growth, inflammatory responses to stress signals and cell differentiation. MAPK pathway, involves three main kinases, Raf, MEK and ERK, has emerged as a novel target for the development of new cancer therapies with reduced side-effects.

MAPK inhibitors are being developed as small molecules, for the treatment of various types of cancer. They have also showed additional benefits with high effectiveness at lower concentrations in comparison to the ATP-competitive inhibitors, for the cancer therapy.
Request to Get the Sample Pages at: 
Mereo BioPharma Group plc is in the process of developing Acumapimod as an oral p38 MAPK inhibitor for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). eFFECTOR Therapeutics Inc., Genentech Inc., and Kura Oncology Inc. are some other companies having pipeline of MAPK inhibitors.


The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.


Share:

MDM2 Protein Inhibitors Therapeutics - Pipeline Analysis 2019


MDM2 protein are powerful oncogene which is overexpressed in various cancers, including breast cancer and sarcoma. There are many small molecule drug candidates that are being developed as MDM2 protein inhibitors as monotherapy or combination therapy for the treatment of various cancers. 
Combination therapies are more effective than monotherapy in certain cases. The therapeutic strategies aim at blocking MDM2 expression, blocking the physical interaction between MDM2 and p53, modulating the E3 ubiquitin ligase activity of MDM2 and targeting the MDM2-p53 (protein–protein) complex, for the treatment of various indications.

Request to Get the Sample Pages at:  

MDM2 protein therapies have shown positive clinical results for the treatment of various cancers. Also, researches have demonstrated that additional biomarkers are required to be identified to increase the chances of clinical success as mutations in p53 can lead to resistance to MDM2 inhibitors.


Daiichi Sankyo Company Limited is in the process of developing DS-3032 as a proto-oncogene protein C MDM2 inhibitor for the treatment of leukemia, and solid cancers. Some of the other companies having pipeline of MDM2 protein inhibitors include Aileron Therapeutics Inc., Amgen Inc., and F. Hoffmann-La Roche Ltd.


Share:

Interleukin Receptor Modulators Therapeutics - Pipeline Analysis 2019, Clinical Trials & Results, Patents


Interleukin receptors are a group of cytokine receptors that are expressed by leukocytes. Interleukin receptors play an important role in the functioning of the immune system. However, with complete knowledge of their role in pathogenesis of different diseases from allergic reactions to autoimmune disorders and even cancer makes these interleukin receptors an attractive target among different available treatment modalities.

Immune-modulatory role of interleukins as well as their direct and indirect contact with apoptosis and other cancer developments, angiogenesis and progression pathways makes them attractive targets for cancer treatment. GlaxoSmithKline plc is in the process of developing GSK2618960 as an interleukin 7 modulator for the treatment of Sjogren's syndrome. Some of the other companies having pipeline of interleukin receptor modulators include Can-Fite BioPharma Ltd., and Pfizer Inc.

Request to Get the Sample Pages at:   https://www.pharmaproff.com/request-sample/1204

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Share:

Endothelin Antagonists Therapeutics - Pipeline Analysis , Patents, Designations, Collaborations, and Other Developments


Endothelin antagonists are drug candidates that acts against endothelin receptors and generate pharmacological actions such as blocking the vasoconstriction and mediate vasodilatation. Endothelin-1 is a peptide which is comprised of 21 amino acids and formed by vascular endothelium. The biological molecule is a potent vasoconstrictor that binds to endothelin receptors A and B. This further leads to the activation of IP3 DA pathway that causes efflux of calcium ions from the endoplasmic reticulum and produce vasoconstriction in the smooth muscles. 

Image result for Endothelin Antagonists images


AbbVie Inc. is in the process of developing ABT-627 as an endothelin receptor antagonist for the treatment of diabetic nephropathy in type 2 diabetes. Idorsia Pharmaceuticals Ltd. is developing ACT-132577 as an endothelin receptor antagonist for the treatment of resistant hypertension. Moreover, Retrophin Inc. is also developing sparsentan as an endothelin receptor antagonist for the treatment of focal segmental glomerulosclerosis. Ligand Pharmaceuticals Inc., and ENB Therapeutics LLC are some other companies having pipeline of endothelin receptor antagonist.
Download Free PDF Sample Copy:
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Share:

Epidermal Growth Factor Receptor (EGFR) Antagonists Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations


Epidermal growth factor receptors (EGFR) are a group of receptor tyrosine kinase (RTK) that plays a major role in cell proliferation, survival and differentiation. In most of the cancer, EGFR are amplified and overexpressed, due to dysregulation, resulting in cancer development.
Image result for Epidermal Growth Factor Receptor

EGFR inhibitors therapies have shown improvement by inhibiting receptor signalling and enhancing the effects of radiation therapy and conventional chemotherapy with their anti-tumor activity. Cetuximab, Panitumumab, Erlotinib and Afatinib are some of the major marketed drugs as anti-EGFR therapies for the treatment of colorectal cancer, head and neck cancer and non-small cell lung cancer.
Download Free PDF Sample Copy:


The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.

Share:

Galectin Inhibitor Therapeutics - Pipeline Analysis , Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments


Galectins belong to the family of animal lectins and perform function by interacting with cytoplasmic and nuclear proteins, cell-surface and extracellular matrix glycoproteins and glycolipids to modulate signalling pathways. Studies have shown the crucial roles of galectin in cancer as they contribute to tumour cell survival, tumour metastasis, angiogenesis and neoplastic transformation.
 Image result for Galectin Inhibitor
Many studies have demonstrated role of galectins in the pathogenesis of various diseases including malignant, fibrotic and inflammatory diseases; hence, emerges as an attractive target for the therapeutic of various diseases. Galectin-3 inhibitors has shown positive clinical results for the treatment of acute lymphoblastic leukemia. Thus, providing several opportunities to the companies for the development of galectin-based therapies for the treatment of multiple human diseases.
Download Free PDF Sample Copy:
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.


Read More..
Share:

Popular Posts

Labels

Linkedin Profile

APSense

Business Network

Recent Posts

Research Pages